UBS Group’s St Jude Medical STJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q1
Sell
-1,343,476
Closed -$108M 8397
2016
Q4
$108M Sell
1,343,476
-366,060
-21% -$29.1M 0.06% 315
2016
Q3
$136M Sell
1,709,536
-569,762
-25% -$46M 0.08% 256
2016
Q2
$178M Buy
2,279,298
+2,050,931
+898% +$146M 0.11% 195
2016
Q1
$12.6M Sell
228,367
-28,386
-11% -$1.55M 0.01% 1175
2015
Q4
$15.9M Sell
256,753
-11,441
-4% -$722K 0.01% 1096
2015
Q3
$16.9M Buy
268,194
+11,843
+5% +$845K 0.01% 1008
2015
Q2
$18.7M Sell
256,351
-10,219
-4% -$738K 0.01% 1023
2015
Q1
$17.4M Sell
266,570
-24,601
-8% -$1.64M 0.01% 1057
2014
Q4
$18.9M Buy
+291,171
New +$18.8M 0.01% 1023

Other funds holding STJ

UBS Group's STJ Position: Q1 2017 in Review

UBS Group sold out of St Jude Medical (STJ) in Q1 2017, closing a stake of 1,343,476 shares — an estimated $108M sold.

UBS Group first reported a position in STJ in Q4 2014 and held it in 9 quarters. The position peaked at $178M in Q2 2016. 4 funds tracked by Wall St. Rank hold STJ as of Q1 2017.

  • UBS Group reported no remaining St Jude Medical position as of Q1 2017 after selling out during the quarter.
  • UBS Group sold 1,343,476 St Jude Medical shares in Q1 2017, an estimated $108M.
  • UBS Group first reported a position in St Jude Medical in Q4 2014 and held it in 9 quarters.
  • UBS Group's St Jude Medical position peaked at $178M in Q2 2016.
  • 4 funds tracked by Wall St. Rank held St Jude Medical as of Q1 2017.

Based on UBS Group's 13F filing for Q1 2017, filed 12 May 2017.